◎ Sugi Atlas

Atlas / Disease / Agoraphobia

Agoraphobia

disease
On this page

Also known as fear of open spaces (finding)

Summary

Agoraphobia (MONDO:0003709) is a disease and 49 clinical trials. Top therapeutic interventions include paroxetine, clonazepam, and cycloserine. A subtype of phobic disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 49

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameagoraphobia
Mondo IDMONDO:0003709
EFOEFO:1001872
MeSHD000379
DOIDDOID:593
ICD-10-CMF40.0
ICD-11530592394
NCITC34362
SNOMED CT70691001
UMLSC0001818
MedGen175
Is cancer (heuristic)no

Also known as: fear of open spaces (finding)

Disease family

This is a subtype of phobic disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › anxiety disorder › phobic disorder › agoraphobia

Related subtypes (2): social phobia, specific phobia

Subtypes (1): panic disorder with agoraphobia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugDevelopment status
ParoxetinePhase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Cycloserine.

Clinical trials & evidence

Clinical trials

Clinical trials: 49.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified37
PHASE44
PHASE34
PHASE22
PHASE2/PHASE31
PHASE1/PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00182533PHASE4TERMINATEDSertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood Disorders
NCT02852577PHASE4COMPLETEDLong Term Treatment of Panic Disorder With Clonazepam or Paroxetine
NCT03522844PHASE4COMPLETEDTreatments for Anxiety: Meditation and Escitalopram
NCT03785223PHASE4COMPLETEDA 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
NCT00000368PHASE3COMPLETEDTreatment of Panic Disorder: Long Term Strategies
NCT00353470PHASE3COMPLETEDComparison of Psychotherapy Programs to Treat Panic Disorder
NCT01323556PHASE2/PHASE3UNKNOWNMechanisms of Panic Disorders Treatment
NCT03549819PHASE3UNKNOWNCannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study
NCT04569760PHASE3WITHDRAWNCannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study
NCT00576719PHASE2COMPLETEDEffectiveness of Intensive Cognitive Behavioral Therapy in Treating Adolescent Panic Disorder and Agoraphobia
NCT01928823PHASE2COMPLETEDAugmentation of Psychotherapy With D-Cycloserine in Agoraphobia
NCT03143634PHASE1/PHASE2COMPLETEDThe Modular Protocol for Mental Health (MPMH)
NCT05118594Not specifiedNOT_YET_RECRUITINGTesting a Precision Psychotherapy System for Low-income Patients
NCT05124639Not specifiedACTIVE_NOT_RECRUITINGClinical Trial of a Group Self-management Support Program for Anxiety Disorders
NCT05427708Not specifiedRECRUITINGRespiratory Training in the Treatment of Transdiagnostic Pathological Anxiety
NCT05671419Not specifiedRECRUITINGMindful Self-Compassion for Anxiety Disorders and Depression
NCT06661460Not specifiedRECRUITINGInternet-Delivered Cognitive Behavioral Intervention for Youths With Anxiety Disorders
NCT06788119Not specifiedRECRUITINGAnalyzing the Benefits of Using SYMPTOMS-JIT for in Vivo Exposure in Anxiety Disorders
NCT06934525Not specifiedRECRUITINGImplementing Team-Based Treatment for Pediatric Anxiety in Community Mental Health Settings
NCT06942429Not specifiedRECRUITINGStepped Versus Stratified Care for Anxiety Disorders in Youth
NCT07028216Not specifiedRECRUITINGMindful Self-compassion for Anxiety and Depression: Impact of Delivery Method
NCT00004366Not specifiedCOMPLETEDPilot Study of Vestibular Rehabilitation Training for Panic Disorder With Vestibular Dysfunction
NCT00129610Not specifiedUNKNOWNStudy of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With Agoraphobia
NCT00202709Not specifiedCOMPLETEDCan Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder?
NCT00734370Not specifiedCOMPLETEDVirtual Reality Exposure Therapy in Agoraphobic Participants
NCT00932919Not specifiedCOMPLETEDThought Field Therapy and Cognitive Therapy for Agoraphobia
NCT01025908Not specifiedCOMPLETEDCognitive Behavior Psychotherapy in Panic Disorder
NCT01446172Not specifiedCOMPLETEDLongterm Outcome of Inpatient Cognitive and Behavioral Therapies for Agoraphobia
NCT01928810Not specifiedCOMPLETEDPhysical Activity and Cognitive Behavioural Therapy in Panic Disorder and Agoraphobia
NCT02150265Not specifiedCOMPLETEDEffectiveness of Six Sessions CBT for Adolescents With Emotional Problems in Community Clinics
NCT02305537Not specifiedCOMPLETEDBuilding an Outcomes Assessment Infrastructure to Assess Anxiety Treatment
NCT02605668Not specifiedCOMPLETEDProviding Tools for Effective Care and Treatment of Anxiety Disorders
NCT02810171Not specifiedCOMPLETEDDimensional Brain Behavior Predictors of CBT Outcomes in Pediatric Anxiety
NCT02811458Not specifiedCOMPLETEDClinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders
NCT03051074Not specifiedCOMPLETEDExamining the Effects of Reduced Environmental Stimulation on Anxiety
NCT03113175Not specifiedCOMPLETEDCollabri Flex - Effect of Collaborative Care for People With Anxiety Disorders in General Practice
NCT03156556Not specifiedCOMPLETEDImproving Access to the Treatment of Anxiety and Depression Among Young Adults
NCT03206437Not specifiedCOMPLETEDEffect of Mindfulness Meditation on Physiological Response to Unpredictable Stimuli
NCT03528109Not specifiedUNKNOWNImproving Access to Child Anxiety Treatment
NCT03684577Not specifiedCOMPLETEDEfficacy of Hypnotherapy for Agoraphobia

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
PAROXETINE42
CLONAZEPAM41
CYCLOSERINE41
METHYLPHENIDATE41
SERTRALINE41
LEVCYCLOSERINE21
CHEMBL178836101

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 22

This page pulls from 22 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardoidefogenccgwasgwas_studyhgncicd10cmicd11medgenmeshmimmondomondochildmondoparentncitorphanetsctidumls